Ownership Change: Francis Sarena an Insider in Five Prime Therapeutics Inc (NASDAQ:FPRX) Unloaded 1,710 Shares

November 30, 2016 - By Richard Conner

Ownership Change: Francis Sarena an Insider in Five Prime Therapeutics Inc (NASDAQ:FPRX) Unloaded 1,710 Shares

Francis Sarena Insider Sell

A legal form filed with the (SEC) on 30/11/2016 revealed that Francis Sarena, the Chief Strategy Officer of Five Prime Therapeutics Inc, ‘s company sold 1,710 shares. With average cost per share of $60.1 the sizable deal’s worth is $102,839 US Dollars. Francis is trying to decrease his company’s share, same as he did in the last 30 days. He sold another 34,654 shares worth $2,092,508 USD. The transaction will most probably not remain disregarded as it was significant one. Now, he has rights to a total of 81,266 shares or 0.30% of the company’s market cap (share price times the number of shares outstanding).

Five Prime Therapeutics Inc (NASDAQ:FPRX) Ratings Coverage

Out of 5 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. $52 is the highest target while $33 is the lowest. The $45.75 average target is -21.11% below today’s ($57.99) stock price. Five Prime Therapeutics has been the topic of 9 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Citigroup initiated Five Prime Therapeutics Inc (NASDAQ:FPRX) on Tuesday, October 25 with “Buy” rating. The firm has “Market Perform” rating given on Tuesday, April 12 by BMO Capital Markets. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. Credit Suisse maintained Five Prime Therapeutics Inc (NASDAQ:FPRX) on Friday, March 11 with “Outperform” rating. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) earned “Sell” rating by Zacks on Tuesday, August 11. Zacks upgraded Five Prime Therapeutics Inc (NASDAQ:FPRX) on Friday, August 21 to “Sell” rating. Oppenheimer maintained the shares of FPRX in a report on Monday, October 19 with “Outperform” rating. Credit Suisse initiated the shares of FPRX in a report on Thursday, January 21 with “Outperform” rating. The company was initiated on Friday, July 31 by Citigroup.

Insitutional Activity: The institutional sentiment decreased to 1.15 in Q2 2016. Its down 1.14, from 2.29 in 2016Q1. The ratio worsened, as 15 funds sold all Five Prime Therapeutics Inc shares owned while 34 reduced positions. 47 funds bought stakes while 65 increased positions. They now own 24.20 million shares or 3.63% more from 23.35 million shares in 2016Q1.

Metropolitan Life Insur has 19,875 shares for 0.01% of their US portfolio. Awm Inc accumulated 0.8% or 90,000 shares. Clarivest Asset Management Limited Liability Corp owns 41,428 shares or 0.05% of their US portfolio. Dekabank Deutsche Girozentrale last reported 0.01% of its portfolio in the stock. Renaissance Techs Ltd Liability has 0.01% invested in the company for 121,300 shares. Oxford Asset Mgmt accumulated 0.18% or 104,202 shares. Grp Inc Inc has 0% invested in the company for 15,532 shares. Us Financial Bank De accumulated 0% or 731 shares. Winslow Evans Crocker holds 0% or 110 shares in its portfolio. Parametric Portfolio Associates Limited Liability owns 43,765 shares or 0% of their US portfolio. Cupps Ltd Limited Liability Company has 0.38% invested in the company for 35,950 shares. Sei Company, a Pennsylvania-based fund reported 915 shares. Moreover, Ladenburg Thalmann Financial Inc has 0% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 222 shares. Group One Trading Ltd Partnership last reported 0% of its portfolio in the stock. Axa last reported 0.01% of its portfolio in the stock.

Insider Transactions: Since July 27, 2016, the stock had 0 insider purchases, and 7 sales for $3.24 million net activity. Sarena Francis Willard also sold $2.09 million worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) shares. $25,385 worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) was sold by RINGO WILLIAM R on Monday, August 1. Jensen Peder sold $449,589 worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) on Wednesday, November 9.

About 103,553 shares traded hands. Five Prime Therapeutics Inc (NASDAQ:FPRX) has risen 22.24% since April 27, 2016 and is uptrending. It has outperformed by 17.01% the S&P500.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The company has a market cap of $1.64 billion. The Firm has three product candidates in clinical development covering multiple potential indications. It has a 7.54 P/E ratio. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

According to Zacks Investment Research, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California.”

Analysts await Five Prime Therapeutics Inc (NASDAQ:FPRX) to report earnings on March, 9. They expect $-0.51 earnings per share, down 104.80% or $11.14 from last year’s $10.63 per share. After $-0.72 actual earnings per share reported by Five Prime Therapeutics Inc for the previous quarter, Wall Street now forecasts -29.17% EPS growth.

Another recent and important Five Prime Therapeutics Inc (NASDAQ:FPRX) news was published by Benzinga.com which published an article titled: “Citi Launches Positive Coverage On Five Prime Therapeutics” on October 25, 2016.

FPRX Company Profile

Five Prime Therapeutics, Inc. (Five Prime), incorporated on December 20, 2001, is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The Firm has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Firm seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>